Humacyte (HUMA) Stock
Biotech company developing living human blood vessel replacements. Here's the price, business snapshot, and what's worth knowing about Humacyte in August 2026.
Humacyte, Inc. (HUMA) is a clinical‑stage biotechnology company developing off‑the‑shelf, human acellular vessels (HAVs) intended to serve as living vascular grafts for people with vascular disease. The technology aims to provide a scalable, implantable conduit for indications such as dialysis access, peripheral arterial disease and surgical bypass. As a small‑cap, clinical‑stage company (market capitalisation around $320m), Humacyte’s value is driven by clinical trial outcomes, regulatory decisions and potential commercial partnerships rather than steady revenue. This profile means shares can be volatile and outcomes binary: positive clinical data or approvals could materially advance prospects, while setbacks may reduce valuation. Investors should consider clinical and regulatory risk, cash runway and dilution potential from future financing. This is educational information only and not financial advice — suitability depends on personal circumstances and investors may lose part or all of their investment.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Humacyte's stock with a target price of $10.42, indicating strong growth potential.
Financial Health
Humacyte is generating modest revenue and cash flow, but faces challenges in profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Trial readouts and regulatory milestones can move the share price significantly, though clinical outcomes are uncertain and binary in nature.
Regenerative Innovation
Off‑the‑shelf human acellular vessels address clear clinical needs and could attract partners, yet commercialisation and manufacturing scale‑up carry execution risk.
Potential Market Reach
Applications include dialysis access and vascular surgery across global markets, but adoption depends on clinical evidence, reimbursement and surgeon preference.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
